Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H22Cl2N4O2 |
| Molecular Weight | 433.331 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NC1=CC(C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(Cl)=CC=C3)=C(Cl)C=N1
InChI
InChIKey=KSERXGMCDHOLSS-LJQANCHMSA-N
InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1
| Molecular Formula | C21H22Cl2N4O2 |
| Molecular Weight | 433.331 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 06:39:23 UTC 2023
by
admin
on
Sat Dec 16 06:39:23 UTC 2023
|
| Record UNII |
16ZDH50O1U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 06:39:23 UTC 2023 , Edited by admin on Sat Dec 16 06:39:23 UTC 2023
|
||
|
NCI_THESAURUS |
C61074
Created by
admin on Sat Dec 16 06:39:23 UTC 2023 , Edited by admin on Sat Dec 16 06:39:23 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C104744
Created by
admin on Sat Dec 16 06:39:23 UTC 2023 , Edited by admin on Sat Dec 16 06:39:23 UTC 2023
|
PRIMARY | |||
|
CHEMBL3545022
Created by
admin on Sat Dec 16 06:39:23 UTC 2023 , Edited by admin on Sat Dec 16 06:39:23 UTC 2023
|
PRIMARY | |||
|
16ZDH50O1U
Created by
admin on Sat Dec 16 06:39:23 UTC 2023 , Edited by admin on Sat Dec 16 06:39:23 UTC 2023
|
PRIMARY | |||
|
DB13930
Created by
admin on Sat Dec 16 06:39:23 UTC 2023 , Edited by admin on Sat Dec 16 06:39:23 UTC 2023
|
PRIMARY | |||
|
9969
Created by
admin on Sat Dec 16 06:39:23 UTC 2023 , Edited by admin on Sat Dec 16 06:39:23 UTC 2023
|
PRIMARY | |||
|
11719003
Created by
admin on Sat Dec 16 06:39:23 UTC 2023 , Edited by admin on Sat Dec 16 06:39:23 UTC 2023
|
PRIMARY | |||
|
DTXSID601025683
Created by
admin on Sat Dec 16 06:39:23 UTC 2023 , Edited by admin on Sat Dec 16 06:39:23 UTC 2023
|
PRIMARY | |||
|
300000013128
Created by
admin on Sat Dec 16 06:39:23 UTC 2023 , Edited by admin on Sat Dec 16 06:39:23 UTC 2023
|
PRIMARY | |||
|
869886-67-9
Created by
admin on Sat Dec 16 06:39:23 UTC 2023 , Edited by admin on Sat Dec 16 06:39:23 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR |
In ABCB1-overexpressing cells, ulixertinib antagonized MDR by attenuating the efflux function of ABCB1. A combination of ulixertinib with anticancer drugs to attenuate MDR mediated by ABCB1 or ABCG2 in cancer cells overexpressing these transporters.
|
||
|
TARGET -> INHIBITOR |
REVERSIBLE
Ki
|
||
|
TRANSPORTER -> INHIBITOR |
In ABCG2-overexpressing cells, ulixertinib inhibited the efflux activity of ABCG2 and reversed resistance to sub-strate anticancer drugs. Mechanistic investigations revealed that ulixertinib stimulated the ATPase activity of both ABCB1 and ABCG2 in a concentration-dependent manner,
|
||
|
TARGET -> INHIBITOR |
competitive with ATP increases in ATP led to increased IC50. Value for 1 micromolar ATP
REVERSIBLE
IC50
|
||
|
TARGET -> INHIBITOR |
REVERSIBLE
Ki
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
